Christopher Viehbacher - Biogen CEO Pres
| BIIB34 Stock | BRL 152.70 2.54 1.69% |
Insider
Christopher Viehbacher is CEO Pres of Biogen Inc
| Age | 63 |
| Phone | 617 679 2000 |
| Web | https://www.biogen.com |
Biogen Management Efficiency
The company has return on total asset (ROA) of 0.076 % which means that it generated a profit of $0.076 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2023 %, meaning that it generated $0.2023 on every $100 dollars invested by stockholders. Biogen's management efficiency ratios could be used to measure how well Biogen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jyoti Mehra | Gilead Sciences | 47 | |
| BCH BM | Bristol Myers Squibb | 57 | |
| Giovanni MD | Bristol Myers Squibb | 58 | |
| Linda Higgins | Gilead Sciences | 61 | |
| David Williams | Merck Co | 54 | |
| Sandra Esq | Bristol Myers Squibb | 62 | |
| Jitendra Tyagi | Bristol Myers Squibb | N/A | |
| Perry Siatis | AbbVie Inc | N/A | |
| Diane Wilfong | Gilead Sciences | 61 | |
| Thomas Hudson | AbbVie Inc | 61 | |
| David Elkins | Bristol Myers Squibb | 55 | |
| Scott Reents | AbbVie Inc | 56 | |
| Jennifer Mauer | Merck Co | N/A | |
| Lisa LeCointeCephas | Merck Co | 41 | |
| Timothy Power | Bristol Myers Squibb | N/A | |
| Caroline Litchfield | Merck Co | 54 | |
| Cristal Downing | Merck Co | 54 | |
| Elizabeth Shea | AbbVie Inc | N/A | |
| Cari Gallman | Bristol Myers Squibb | N/A | |
| Peter Dannenbaum | Merck Co | N/A | |
| Deborah Telman | Gilead Sciences | 58 | |
Management Performance
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 |
Biogen Inc Leadership Team
Elected by the shareholders, the Biogen's board of directors comprises two types of representatives: Biogen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biogen. The board's role is to monitor Biogen's management team and ensure that shareholders' interests are well served. Biogen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biogen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christopher Viehbacher, CEO Pres | ||
| Robin Kramer, Chief Accounting Officer, Vice President | ||
| Sanjay Jariwala, Senior Vice President - Worldwide Medical | ||
| Ginger Gregory, Chief Human Resource Officer, Executive Vice President | ||
| Anabella Villalobos, Senior Vice President - Biotherapeutic & Medicinal Sciences (BTMS) | ||
| Susan Esq, Chief VP | ||
| Michael CPA, Ex CFO | ||
| Natacha Gassenbach, Chief Affairs | ||
| Nicole Murphy, Head Technology | ||
| Michael Hencke, Head Relations |
Biogen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biogen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | |||
| Return On Asset | 0.076 | |||
| Profit Margin | 0.28 % | |||
| Operating Margin | 0.29 % | |||
| Current Valuation | 230.79 B | |||
| Shares Outstanding | 867.48 M | |||
| Price To Earning | 6.38 X | |||
| Price To Book | 3.28 X | |||
| Price To Sales | 21.53 X | |||
| Revenue | 10.98 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Biogen Stock
When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.